Emerging strategies for managing peptic ulcer disease

Area of Science:

• Gastroenterology
• Pharmacology
• Clinical Medicine

Background:

• Intragastric acidity inhibition is crucial for ulcer healing, particularly for duodenal ulcers.
• Omeprazole demonstrates superior efficacy over H2-receptor antagonists in healing duodenal ulcers and alleviating symptoms.
• Current peptic ulcer management is shifting towards H. pylori eradication strategies.

Purpose of the Study:

• To compare the efficacy of omeprazole with H2-receptor antagonists in treating duodenal and gastric ulcers.
• To evaluate the cost-effectiveness and symptom resolution associated with omeprazole treatment.
• To explore the role of combination therapies in managing peptic ulcer disease and preventing relapse.

Main Methods:

• Comparative clinical trials assessing ulcer healing rates and symptom resolution.
• Evaluation of treatment durations and cost-effectiveness of omeprazole versus H2-receptor antagonists.
• Analysis of H. pylori eradication regimens in combination with omeprazole.

Main Results:

• Omeprazole is more effective than H2-receptor antagonists for duodenal ulcer healing and symptom resolution, with shorter treatment durations.
• Omeprazole also shows superior efficacy in healing gastric ulcers and resolving symptoms compared to H2-receptor antagonists.
• Combination therapies with omeprazole, amoxicillin, or clarithromycin are effective for H. pylori eradication and ulcer healing, preventing relapse.

Conclusions:

• Omeprazole represents a more effective and cost-efficient treatment for both duodenal and gastric ulcers.
• Combination therapies integrating omeprazole are emerging as the standard for future peptic ulcer disease management.
• Omeprazole is the preferred treatment for NSAID-induced ulcers, even with continued NSAID use.